Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS
The river diagram demonstrates that after transjugular intrahepatic portosystemic shunt insertion (TIPS) the majority of patients without ascites and 50% of the patients with ascites detectable at ultrasound, show the best response in the long term follow‐up.
Alexander Queck +14 more
wiley +1 more source
Modulation of the microbiota across different intestinal segments by Rifaximin in PI-IBS mice
Background Rifaximin has been increasingly applied in irritable bowel syndrome (IBS) treatment. Whether there were differences in the effects of rifaximin on microbiota from different intestinal segments, especially the small intestine where rifaximin ...
Shengyan Zhang +5 more
doaj +1 more source
Background and Aims:. Hepatic encephalopathy (HE) is associated with significant morbidity and mortality for those with cirrhosis. Despite the known benefits of rifaximin use for HE, treatment retention remains low.
Elizabeth S. Aby +4 more
doaj +1 more source
Rifaximin-mediated changes to the epithelial cell proteome: 2-D gel analysis. [PDF]
Rifaximin is a semi-synthetic rifamycin derivative that is used to treat different conditions including bacterial diarrhea and hepatic encephalopathy.
Caroline Schrodt +4 more
doaj +1 more source
The role of rifaximin in irritable bowel syndrome derived from a network meta-analysis of randomized control trials [PDF]
Objective: Recent randomized control trials (RCTs), have demonstrated the beneficial therapeutic effects of rifaximin for the treatment of the irritable bowel syndrome (IBS).
T. Rokkas +8 more
doaj +1 more source
Effect of rifaximin in the prevention of acute kidney injury and hepatorenal syndrome type II in Egyptian cirrhotic patients [PDF]
Background: Hepatorenal syndrome type II and acute kidney injury found in 20% of cirrhotic patients. Rifaximin was found to reduce the frequency of hepatorenal syndrome type II and acute kidney injury in alcohol cirrhotic patients.
Ahmed El-Gebaly +2 more
doaj +1 more source
Dysbiosis in the small intestine: towards an optimal therapy to normalize the gut microbiota [PDF]
Objectives: Rifaximin seems to be effective and safe in treating small intestinal bacterial overgrowth (SIBO), however, to date there is no consensus regarding the proper timing of therapy. The present study aims to provide preliminary data regarding the
G. Gasbarrini +4 more
doaj +1 more source
Rifaximin use favoured micafungin-resistant Candida spp. infections in recipients of allogeneic hematopoietic cell transplantation [PDF]
Damage to gut mucosa following conditioning regimens may favour bacterial infections that can trigger graft versus host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Rifaximin, an oral and non-absorbable
Ruggeri, Loredana +16 more
core +2 more sources
Objective: Rifaximin has been approved for use as a first-line therapy for secondary prophylaxis of hepatic encephalopathy (HE). This article is to update existing evidence on efficacy and safety of rifaximin treatment and prevention for HE.Methods: We ...
Xianghui Han +8 more
doaj +1 more source
: Objectives: This study was designed to investigate the molecular epidemiology of Clostridioides difficile isolates in South Korea and to evaluate risk factors for rifaximin-non-susceptible C. difficile infection (CDI). Methods: A total of 413 patients
Dokyun Kim +5 more
doaj +1 more source

